Core Viewpoint - Heng Rui Medicine has received approval from the National Medical Products Administration for clinical trials of HRS-5041, a new drug aimed at treating prostate cancer, indicating a significant advancement in its product pipeline [1] Group 1: Product Development - HRS-5041 is a novel, efficient, and selective AR-PROTAC small molecule developed by the company [1] - The drug demonstrates significant degradation effects on wild-type and various mutant AR proteins, showing potential to overcome resistance compared to second-generation AR inhibitors [1] - Currently, there are no similar products approved for market in both domestic and international markets [1] Group 2: Financial Investment - The cumulative research and development investment for the HRS-5041 project has reached approximately 69.19 million yuan [1]